As prices for Ozempic have risen in recent months, many people may be seeking cheaper alternatives for managing diabetes or weight loss. Dr. Brett Osborn and Dr. Sue Decotiis warn of potential risks.

The US regulator has said that compounders can continue to trade in tirzepatide products while it undertakes a review to ...

New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.

The future of the weight loss market might not revolve around GLP-1 drugs.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Read which pharmaceutical companies are addressing the risk of muscle mass loss associated with popular weight loss drugs from Novo (NOVO) and Eli Lilly (LLY).

Researchers at Massachusetts General Hospital have discovered that meeting the weekly recommended physical activity levels, ...

A pharmacist warns that off-brand Ozempic, Zepbound, and other weight loss products carry undisclosed risks for consumers.

Danish drug maker Novo Nordisk has struck partnerships with 10 Indian artificial intelligence (AI) startups to streamline its ...

Davis-based biological controls company Invasive Species Corp., founded by biologics pioneer Pam Marrone, has taken office ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's ...